Stock listing
NASDAQ:IMMX Immix Biopharma, Inc. Stock
Home listing (NASDAQ) of Immix Biopharma, Inc.
Follow Immix Biopharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IMMX
$6.96 USD -0.15 (-2.1%)
Close on Nov 20, 2026
- Day range
- $6.90 – $7.50 USDNov 20, 2026
- Volume
- 1.57M sharesNov 20, 2026
- Market cap
- $577.0M USDAt the close on Nov 20, 2026 · price × 82.90M shares outstanding
- 52-week range
- $3.78 – $15.10 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $15.43M USDMedian day 1.29M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IMMX · Home | $6.96 USD | -0.15 (-2.1%) | 1,572,782 | $6.99 | $7.50 | $6.90 | $7.11 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMMX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.96 | -0.15 | -2.1% | $6.99 | $7.50 | $6.90 | 1,572,782 | |
| $7.11 | -0.09 | -1.2% | $7.235 | $7.43 | $7.05 | 876,255 | |
| $7.20 | -0.28 | -3.7% | $7.48 | $7.52 | $7.12 | 993,758 | |
| $7.48 | -0.36 | -4.6% | $7.83 | $8.01 | $7.455 | 1,004,634 | |
| $7.84 | -0.23 | -2.9% | $8.25 | $8.375 | $7.66 | 1,027,813 | |
| $8.07 | -0.59 | -6.8% | $8.40 | $8.45 | $8.06 | 954,606 | |
| $8.66 | +0.31 | +3.7% | $8.40 | $8.72 | $8.30 | 1,070,704 | |
| $8.35 | -0.22 | -2.6% | $8.37 | $8.77 | $8.132 | 825,479 | |
| $8.57 | +0.51 | +6.3% | $8.09 | $8.89 | $7.90 | 1,270,839 | |
| $8.06 | +0.86 | +11.9% | $7.24 | $8.17 | $7.18 | 1,444,882 | |
| $7.20 | -0.77 | -9.7% | $7.86 | $7.95 | $7.12 | 1,414,576 | |
| $7.97 | +0.26 | +3.4% | $7.93 | $8.16 | $7.56 | 1,249,715 | |
| $7.71 | +0.45 | +6.2% | $7.33 | $7.80 | $7.168 | 1,072,329 | |
| $7.26 | -0.42 | -5.5% | $7.65 | $7.913 | $7.185 | 1,506,997 | |
| $7.68 | -0.30 | -3.8% | $7.86 | $8.10 | $7.56 | 1,381,203 | |
| $7.98 | -0.145 | -1.8% | $8.11 | $8.36 | $7.835 | 1,073,785 | |
| $8.125 | +0.075 | +0.9% | $7.98 | $8.21 | $7.88 | 1,229,694 | |
| $8.05 | -0.01 | -0.1% | $8.00 | $8.16 | $7.849 | 1,147,026 | |
| $8.06 | -0.09 | -1.1% | $8.17 | $8.31 | $7.99 | 1,116,278 | |
| $8.15 | -0.20 | -2.4% | $8.34 | $8.89 | $7.88 | 1,203,479 | |
| $8.35 | -0.16 | -1.9% | $8.40 | $8.73 | $8.23 | 817,970 | |
| $8.51 | -0.40 | -4.5% | $8.94 | $9.10 | $8.47 | 1,540,507 | |
| $8.91 | +0.69 | +8.4% | $8.26 | $9.03 | $8.235 | 1,226,147 | |
| $8.22 | +0.24 | +3.0% | $8.05 | $8.35 | $8.00 | 1,302,419 | |
| $7.98 | -0.70 | -8.1% | $8.67 | $8.67 | $7.95 | 1,503,800 | |
| $8.68 | +0.17 | +2.0% | $8.51 | $8.905 | $8.45 | 1,314,400 | |
| $8.51 | -0.18 | -2.1% | $8.60 | $8.87 | $8.42 | 1,360,500 | |
| $8.69 | -0.56 | -6.1% | $9.10 | $9.29 | $8.66 | 1,483,600 | |
| $9.25 | -0.21 | -2.2% | $9.42 | $9.56 | $9.18 | 936,200 | |
| $9.46 | +0.17 | +1.8% | $9.29 | $9.53 | $9.18 | 1,109,000 | |
| $9.29 | -0.20 | -2.1% | $9.34 | $9.37 | $8.96 | 1,289,000 | |
| $9.49 | -0.15 | -1.6% | $9.50 | $9.69 | $9.40 | 1,382,100 | |
| $9.64 | -0.49 | -4.8% | $10.20 | $10.20 | $9.515 | 1,214,600 | |
| $10.13 | +0.45 | +4.6% | $9.71 | $10.33 | $9.55 | 1,597,500 | |
| $9.68 | -0.55 | -5.4% | $10.35 | $10.37 | $9.48 | 2,548,000 | |
| $10.23 | -0.175 | -1.7% | $10.25 | $10.48 | $9.86 | 1,648,300 | |
| $10.41 | -0.135 | -1.3% | $10.61 | $11.25 | $10.39 | 2,408,600 | |
| $10.54 | -0.93 | -8.1% | $11.64 | $11.85 | $10.07 | 5,759,500 | |
| $11.47 | +0.50 | +4.6% | $10.82 | $11.84 | $10.70 | 995,600 | |
| $10.97 | -0.73 | -6.2% | $11.78 | $11.99 | $10.82 | 1,828,200 | |
| $11.70 | -0.22 | -1.8% | $11.87 | $11.97 | $11.19 | 1,535,800 | |
| $11.92 | -0.91 | -7.1% | $12.80 | $12.84 | $11.71 | 1,168,200 | |
| $12.83 | +0.36 | +2.9% | $12.45 | $12.90 | $12.31 | 948,100 | |
| $12.47 | -0.03 | -0.2% | $12.59 | $12.71 | $12.14 | 1,329,500 | |
| $12.50 | -0.22 | -1.7% | $12.68 | $12.84 | $12.34 | 4,183,900 | |
| $12.72 | +0.80 | +6.7% | $12.24 | $12.75 | $12.07 | 1,184,700 | |
| $11.92 | -0.22 | -1.8% | $12.28 | $12.46 | $11.75 | 1,421,900 | |
| $12.14 | -0.07 | -0.6% | $12.49 | $12.63 | $11.81 | 1,054,900 | |
| $12.21 | +0.07 | +0.6% | $12.44 | $12.59 | $11.98 | 1,079,600 | |
| $12.14 | -0.56 | -4.4% | $12.86 | $13.29 | $12.02 | 1,190,300 | |
| $12.70 | +0.39 | +3.2% | $12.08 | $12.77 | $11.91 | 1,656,300 | |
| $12.31 | -0.94 | -7.1% | $13.12 | $13.23 | $12.24 | 1,285,600 | |
| $13.25 | -0.66 | -4.7% | $13.70 | $13.89 | $12.75 | 1,420,200 | |
| $13.91 | +0.08 | +0.6% | $13.68 | $14.09 | $13.60 | 1,050,700 | |
| $13.83 | -0.13 | -0.9% | $14.14 | $14.14 | $13.52 | 987,200 | |
| $13.96 | -0.05 | -0.4% | $14.00 | $14.23 | $13.42 | 1,578,200 | |
| $14.01 | -0.02 | -0.1% | $13.86 | $14.26 | $13.62 | 1,277,400 | |
| $14.03 | +0.09 | +0.6% | $13.70 | $14.15 | $13.52 | 1,326,800 | |
| $13.94 | -0.37 | -2.6% | $14.06 | $14.17 | $13.76 | 1,143,400 | |
| $14.31 | +0.24 | +1.7% | $14.03 | $14.61 | $13.77 | 1,511,000 | |
| $14.07 | -0.40 | -2.8% | $14.45 | $14.55 | $13.80 | 1,385,000 | |
| $14.47 | +0.86 | +6.3% | $13.60 | $15.10 | $13.49 | 3,651,500 | |
| $13.61 | -0.05 | -0.4% | $13.66 | $13.80 | $12.90 | 1,415,400 | |
| $13.66 | +0.50 | +3.8% | $13.36 | $13.76 | $13.12 | 1,510,600 | |
| $13.16 | -0.03 | -0.2% | $12.98 | $13.20 | $12.69 | 1,666,200 |
- Ticker
- NASDAQ:IMMX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 34 slides
Latest news
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Nov 12, 2026
Closed $7.84 (-2.9%) on Nov 13, 2026
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
Nov 4, 2026
Closed $7.97 (+3.4%) on Nov 4, 2026
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Oct 5, 2026
Closed $10.13 (+4.6%) on Oct 5, 2026
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Sep 30, 2026
Closed $10.23 (-1.7%) on Oct 1, 2026
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Sep 29, 2026
Closed $10.54 (-8.1%) on Sep 29, 2026
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refracto...
Sep 29, 2026
Closed $10.54 (-8.1%) on Sep 29, 2026
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Aug 4, 2026
Closed $9.33 (+10.8%) on Aug 4, 2026
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
May 22, 2026
Closed $8.84 (+0.7%) on May 26, 2026
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
May 21, 2026
Closed $8.67 (-3.0%) on May 21, 2026
Immix Biopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 106 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 25 decks · latest September 2026
Where Immix Biopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IMMX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IMMX | BOATS | United States | USD |
Valuation
Price/book 1.7× against a median of 2.4×: 4th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $241.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.60
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Immix Biopharma, Inc. · NASDAQ:IMMX | US$577.0M | US$241.7M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.60 |
| Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637 | US$608.9M | US$483.6M | n/a | 106× | n/a | 2.9× | n/a | 0.4× | n/a |
| Annexon, Inc. · NASDAQ:ANNX | US$587.7M | US$423.7M | n/a | n/a | n/a | 4.1× | n/a | 0.3× | 1.63 |
| Design Therapeutics, Inc. · NASDAQ:DSGN | US$577.6M | US$371.5M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.29 |
| Cullinan Therapeutics, Inc. · NASDAQ:CGEM | US$577.1M | US$289.6M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 1.45 |
| Entera Bio Ltd. · NASDAQ:ENTX | US$574.8M | US$308.9M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | 0.76 |
| DBV Technologies SA · EURONEXT:DBV | US$571.8M | US$430.7M | n/a | 47.1× | n/a | 3.9× | n/a | 0.1× | n/a |
| Ascletis Pharma, Inc. · HKEX:1672 | US$571.3M | US$232.4M | n/a | 765× | n/a | 1.7× | n/a | 0.0× | n/a |
| 4D Molecular Therapeutics, Inc. · NASDAQ:FDMT | US$565.1M | US$277.8M | n/a | 2.9× | n/a | 1.7× | −208.6% | 0.1× | 1.75 |
| Bicara Therapeutics Inc. · NASDAQ:BCAX | US$560.3M | US$118.8M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.37 |
| Lepu Biopharma Co. Ltd. Class H · HKEX:2157 | US$554.8M | US$613.4M | 14.6× | 4.5× | 22.9× | 2.6× | 28.0% | 0.8× | n/a |
| Median of the others | US$573.3M | US$340.2M | 14.6× | 47.1× | 22.9× | 2.4× | −90.3% | 0.0× | 1.41 |
Forecasts
4 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 23.80 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.72 · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ilya Rachman | Chief Executive and Scientific Officer |
| Gabriel Morris | President and Chief Financial Officer |
| David He | Head of Technical Operations |
| David Marks | Chief Medical Officer |
| Michael Grabow | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Carey Ng | Independent Director |
| Helen Adams | Independent Director |
| Jane Buchan | Independent Director |
| Jason Hsu | Independent Director |
| Magda Marquet | Independent Director |
| Nancy Chang | Independent Director |
| Yekaterina Chudnovsky | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −2.9% |
| Q2 2026 | Aug 7, 2026 | +0.7% |
| Q1 2026 | May 7, 2026 · After close | +2.2% |
| Q4 2025 | Feb 25, 2026 | 0.0% |
| Q3 2025 | Nov 7, 2025 · After close | +2.9% |
| Q2 2025 | Aug 8, 2025 · After close | −2.9% |
| Q1 2025 | May 8, 2025 · After close | −2.6% |
| Q4 2024 | Feb 26, 2025 | −3.1% |
| Q3 2024 | Nov 12, 2024 · After close | −8.7% |
| Q2 2024 | Aug 12, 2024 · After close | +0.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | 0.0% |
| Q4 2023 | Mar 29, 2024 · After close | −4.9% |
| Q3 2023 | Nov 13, 2023 · Before open | +1.4% |
| Q2 2023 | Aug 11, 2023 · After close | +0.6% |
| Q1 2023 | May 12, 2023 · After close | −3.3% |
| Q4 2022 | Mar 27, 2023 · Before open | +1.6% |
| Q3 2022 | Nov 9, 2022 · After close | −4.7% |
| Q2 2022 | Aug 12, 2022 · After close | −4.5% |
| Q1 2022 | May 13, 2022 · After close | +1.9% |
| Q4 2021 | Mar 28, 2022 · After close | +11.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 34 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 31 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 50 slides | May 2026 |
| Investor Presentation (March 2026) | Investor deck | 48 slides | March 2026 |
| Technical Presentation (February 2026) | Technical | 17 slides | Feb 6, 2026 |
| Investor Presentation (January 2026) | Investor deck | 48 slides | January 2026 |
| ASH 2025 Oral Presentation | Conference | 14 slides | Dec 7, 2025 |
| Investor Presentation (December 2025) | Investor deck | 41 slides | December 2025 |
| Investor Presentation (November 2025) | Investor deck | 40 slides | November 2025 |
| Investor Presentation (September 2025) | Investor deck | 54 slides | September 2025 |
All 25 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2025) | Investor deck | 54 slides | August 2025 |
| Investor Presentation (July 2025) | Investor deck | 54 slides | July 2025 |
| ASCO 2025 | Conference | 13 slides | Jun 3, 2025 |
| ASCO 2025 | Conference | 13 slides | Jun 3, 2025 |
| Investor Presentation (June 2025) | Investor deck | 54 slides | June 2025 |
| Investor Presentation (May 2025) | Investor deck | 57 slides | May 2025 |
| Investor Presentation (April 2025) | Investor deck | 58 slides | April 2025 |
| Investor Presentation (March 2025) | Investor deck | 61 slides | March 2025 |
| Investor Presentation (February 2025) | Investor deck | 61 slides | February 2025 |
| 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 | Conference | 17 slides | Dec 10, 2024 |
| Investor Presentation (October 2024) | Investor deck | 48 slides | October 2024 |
| Investor Presentation (August 2024) | Investor deck | 40 slides | August 2024 |
| Investor Presentation (July 2024) | Investor deck | 40 slides | July 2024 |
| ASGCT 2023 | Conference | 25 slides | May 2023 |
| Investor Presentation (December 2022) | Investor deck | 17 slides | Dec 16, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$125M · US$11 a share · J.P. Morgan Dealers: J.P. Morgan (lead) Buyers: Eventide Asset Management; Janus Henderson Investors; Ridgeback Capital Investments L.P.; Wellington Management Use of proceeds: Fund NXC-201 development, working capital and general corporate purposes | Sep 29, 2026 |
| Public offering of common stock and pre-funded warrants Announced: US$100M · US$5.1 a share · Morgan Stanley +2 Dealers: Morgan Stanley (lead), Citizens Capital Markets, Mizuho Use of proceeds: Fund NXC-201 development, working capital and general corporate purposes | Dec 7, 2025 |
| Strategic investment of strategic investment Closed: strategic investment Buyers: Goose Capital; Dr. Nancy T. Chang | Sep 8, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a share on Dec 15, 2021.
- Price
- US$5.00 a share
- Shares offered
- 4,200,000 shares of common stock
- Offering size
- US$21 million
- Underwriters' option
- Up to 630,000 more shares
- Listing
- IMMX on the Nasdaq Capital Market
- Underwriter
- ThinkEquity
- Shares delivered
- On or about Dec 20, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 20, 2021 |
| Filed publicly | Sep 17, 2021 |
| Amended 4 times | Newest Nov 4, 2021 |
| Shares registered with an exchange | Dec 13, 2021 |
| Declared effective by the SEC | Dec 15, 2021 |
| Final prospectus, with the price | Dec 17, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 17, 2021 |
| EFFECT · Notice that a registration is effective | Dec 15, 2021 |
| CERT · Exchange's certificate of listing | Dec 14, 2021 |
| CORRESP · Letter to the SEC | Dec 13, 2021 |
| CORRESP · Letter to the SEC | Dec 13, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 13, 2021 |
| FWP · Free writing prospectus | Dec 1, 2021 |
| S-1/A · Registration statement, amended | Nov 4, 2021 |
| S-1/A · Registration statement, amended | Oct 28, 2021 |
| S-1/A · Registration statement, amended | Oct 15, 2021 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 15, 2021 |
| UPLOAD · Letter from the SEC | Oct 13, 2021 |
| CORRESP · Letter to the SEC | Oct 6, 2021 |
| S-1/A · Registration statement, amended | Oct 6, 2021 |
| UPLOAD · Letter from the SEC | Sep 27, 2021 |
| S-1 · Registration statement | Sep 17, 2021 |
| CORRESP · Letter to the SEC | Sep 16, 2021 |
| UPLOAD · Letter from the SEC | Aug 16, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jul 20, 2021 |
| DRS · Draft registration statement | Jul 20, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 17, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | -89.5M | 0 | 0 | 0 |
| Cost of revenue | 364.5K | 115.4K | 5.47K | 2.13K | 2.47K | 2.32K | 1.08K |
| Gross profit | -364.5K | -115.4K | -5.47K | -89.5M | -2.47K | -2.32K | -1.08K |
| Research and development | 16.3M | 11.3M | 8.74M | 4.20M | 126.5K | 248.1K | 583.2K |
| Selling, general and administrative | 13.7M | 11.4M | 7.41M | 4.02M | 1.23M | 205.7K | 259.3K |
| Operating income | -30.0M | -22.7M | -16.1M | -8.22M | -1.35M | -453.9K | -842.5K |
| Depreciation and amortization | 245.7K | 32.9K | 5.47K | 2.13K | 2.47K | 2.32K | 1.08K |
| EBITDA | -29.7M | -22.6M | -16.1M | -8.22M | -1.35M | -451.5K | -841.4K |
| Interest expense | 0 | 497 | 179.9K | 102.0K | 110.0K | ||
| Income before tax | -29.4M | -21.7M | -15.6M | -8.22M | -24.4M | -1.13M | -952.3K |
| Income tax | 37.7K | 41.0K | 26.4K | 10.3K | 6.01K | 17.5K | 20.6K |
| Net income | -29.4M | -21.6M | -15.4M | -8.23M | -24.4M | -1.15M | -972.8K |
| Earnings per share, basic | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.34 | -0.29 |
| Earnings per share, diluted | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.34 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 93.9M | 17.7M | 17.5M | 13.4M | 17.6M | 391.1K | 734.0K |
| Short-term investments | 6.48M | 0 | |||||
| Receivables | 1.97M | 1.17M | 255.7K | 25.7K | 127.4K | 175.7K | |
| Current assets | 101.2M | 20.2M | 19.8M | 14.9M | 18.2M | 532.2K | 933.3K |
| Property, plant and equipment | 2.52M | 1.74M | 50.2K | 3.56K | 5.70K | 7.36K | 9.68K |
| Total assets | 104.8M | 22.9M | 19.9M | 14.9M | 18.2M | 539.6K | 942.9K |
| Accounts payable | 5.44M | 5.39M | 1.43M | 143.1K | 142.9K | 252.3K | 247.5K |
| Current liabilities | 10.1M | 8.69M | 3.72M | 1.27M | 202.0K | 5.27M | 4.59M |
| Total debt | 1.07M | 1.07M | 50.0K | 4.10M | 4.10M | ||
| Total liabilities | 11.0M | 9.70M | 3.72M | 1.75M | 202.0K | 5.27M | 4.59M |
| Shareholders' equity | 93.8M | 13.3M | 16.4M | 13.2M | 18.0M | -4.73M | -3.65M |
| Shares outstanding | 53.0M | 27.5M | 19.9M | 13.9M | 13.2M | 3.38M | 3.38M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -23.9M | -14.6M | -11.4M | -7.41M | -1.59M | -404.7K | -790.0K |
| Capital spending | -732.9K | -1.18M | -52.1K | -3 | -802 | -4 | -7.31K |
| Free cash flow | -24.7M | -15.8M | -11.4M | -7.41M | -1.59M | -404.7K | -797.3K |
| Cash from investing | -7.21M | -1.18M | -52.1K | -802 | -802 | -7.31K | |
| Cash from financing | 107.4M | 15.9M | 15.5M | 3.23M | 18.8M | 18.8M | 1.05M |
| Share buybacks | -44.0K | -100.0K | 0 | ||||
| Change in cash | 76.2M | 172.2K | 4.07M | -4.21M | 17.3M | -342.9K | 271.7K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| FWP · Free writing prospectus | Sep 29, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Sep 29, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 29, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| 424B5 · Prospectus | May 21, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | May 21, 2026 | Offer document | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 4, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 6, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 6, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 30, 2026 | Current report | SEC |
| 10-K/A · Annual report, amended | Mar 27, 2026 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 25, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 25, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 23, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 16, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 16, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 8, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| FWP · Free writing prospectus | Dec 8, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 2, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 26, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| S-3 · Registration statement | Oct 6, 2025 | Offer document | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jun 23, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 3, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 3, 2025 | Material contract | SEC |
| ARS · Annual report to shareholders | May 19, 2025 | Annual report | SEC |
| 10-Q/A · Quarterly report, amended | May 19, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 19, 2025 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | May 19, 2025 | Annual report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 2, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 26, 2024 | Current report | SEC |
| 8-K · Current report | Jul 19, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jul 19, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 21, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 20, 2024 | Financing | SEC |
| D | May 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Feb 16, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Feb 7, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Feb 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Feb 5, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | Nov 9, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 9, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 29, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 26, 2023 | Other filings | SEC |
| S-3 · Registration statement | Sep 25, 2023 | Offer document | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2023 | Insider trade | SEC |
| SC 13D · Big-stake notice | Aug 30, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 23, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 23, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 22, 2023 | Material contract | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 424B5 · Prospectus | Jul 14, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 14, 2023 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jun 13, 2023 | Offer document | SEC |
| 8-K · Current report | Jun 8, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2023 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 25, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Mar 27, 2023 | Annual report | SEC |
| 424B5 · Prospectus | Mar 22, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 22, 2023 | Material contract | SEC |
| 8-K/A · Current report, amended | Mar 13, 2023 | Current report | SEC |
| 8-K · Current report | Mar 10, 2023 | Material contract | SEC |
| 8-K · Current report | Jan 18, 2023 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jan 12, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 9, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 6, 2023 | Other filings | SEC |
| S-3 · Registration statement | Jan 3, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2022 | Current report | SEC |
| 8-K · Current report | Dec 14, 2022 | Material contract | SEC |
| 4 · Change in ownership | Nov 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 15, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2022 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 12, 2022 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | Jul 22, 2022 | Insider trade | SEC |
| RW · Request to withdraw a registration | Jul 18, 2022 | Other filings | SEC |
| 4 · Change in ownership | Jul 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2022 | Insider trade | SEC |
| RW WD | Jun 30, 2022 | Other filings | SEC |
| 8-K · Current report | Jun 9, 2022 | Meeting outcome | SEC |
| FWP · Free writing prospectus | May 27, 2022 | Offer document | SEC |
| S-1 · Registration statement | May 27, 2022 | Offer document | SEC |
| DRS · Draft registration statement | May 23, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2022 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2022 | Meeting notice | SEC |
This page holds 200 of 248 filings. Open Filings
Cap table
Built by 6ix from Immix Biopharma, Inc.’s releases · as of Sep 29, 2026
- Common shares
- 82,902,951
- Fully diluted
- 82,902,951
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 82,902,951 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 82,902,951 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Nancy Chang Other companies: Galera Therapeutics, Inc. (Director · Since at least Dec 30, 2024); W&T Offshore, Inc. (Director · Since at least Apr 28, 2023); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); SciClone Pharmaceuticals Inc (Director · Sep 17, 2013 – Oct 13, 2017 · Past); Charles River Laboratories International, Inc. (Director · Oct 24, 2007 – May 7, 2010 · Past); Tanox Inc (Director · Dec 31, 2005 – Nov 2, 2006 · Past) | Independent Director · Since at least Sep 8, 2025 |
| Magda Marquet Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Jun 15, 2026) | Director · Since at least May 22, 2026 |
| Carey Ng | Independent Director · Since at least Dec 15, 2021 |
| David He | Head of Technical Operations · Since at least Nov 4, 2026 |
| David Marks | Chief Medical Officer · Since at least Nov 5, 2026 |
| Gabriel Morris | President and Chief Financial Officer · Since at least Jul 14, 2022 |
| Graham Ross | CMO & Head of Clinical Dev. · Dec 15, 2021 – Dec 15, 2021 · Past |
| Helen Adams | Director · Since at least May 15, 2024 |
| Ilya Rachman | Chief Executive and Scientific Officer · Since at least Dec 15, 2021 |
| Jane Buchan | Director · Since at least May 22, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Jason Hsu | Independent Director · Since at least Dec 15, 2021 |
| Michael Grabow | Chief Commercial Officer · Since at least Nov 12, 2025 |
| Vladimir P Torchilin | Scientific Co-Founder · Dec 15, 2021 – Dec 20, 2021 · Past |
| Yekaterina Chudnovsky | Director · Since at least May 22, 2026 |
Log in to ask 6ix AI your own questions about Immix Biopharma, Inc.